C1orf144 Inhibitors
C1orf144 inhibitors encompass a variety of chemical compounds that interface with specific signaling pathways or biological processes to diminish the functional activity of the C1orf144 protein. These inhibitors are not merely general antagonists; they target unique molecular cascades to which C1orf144 is inherently connected, either through direct participation or indirect regulation. For instance, inhibitors that block the PI3K/Akt pathway, such as LY 294002, would reduce C1orf144 activity if the protein functioned downstream of this pathway. Similarly, if C1orf144 were part of cell cycle control mechanisms, compounds like ZM-447439, which inhibit Aurora kinases, would impede the protein's role in mitotic processes. The specificity of these inhibitors is crucial, as they are designed to attenuate C1orf144 activity by interfering with a specific molecular interaction or signaling event that is pivotal for the protein's activity, rather than eliciting a broad, non-specific downregulation of cellular pathways.
The inhibitors' mechanisms of action are diverse, yet all converge on the common goal of restraining C1orf144's activity. For example, PD 98059 and U0126 are both MEK inhibitors that could suppress C1orf144 if it is a downstream effector in the MAPK/ERK pathway. Proteasome inhibitors like Bortezomib may reduce C1orf144 levels by preventing the degradation of proteins that regulate its activity, indicating an indirect approach to inhibition. In the realm of metabolic control, WZB117's inhibition of glucose transport could reduce C1orf144 activity by depriving it of the necessary energy or substrates required for its function. Each inhibitor thus serves as a targeted strategy to temper C1orf144, whether it is through kinase inhibition, metabolic interference, or modulation of protein stability, reflecting a comprehensive approach to diminishing the protein's activity without affecting the broader cellular function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, LY 294002 leads to the inhibition of the Akt/PKB signaling pathway. If C1orf144 is downstream of PI3K/Akt and plays a role in cell survival or proliferation, LY 294002 would diminish its functional activity by preventing its activation through the pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As a selective inhibitor of MEK, PD 98059 blocks the MAPK/ERK pathway. If C1orf144 is involved in this pathway, possibly as a downstream effector, PD 98059 would lead to a decrease in C1orf144's function by preventing the phosphorylation events required for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a known inhibitor of p38 MAPK. If C1orf144 action is contingent upon p38 MAPK-mediated signaling, inhibition by SB 203580 would result in diminished C1orf144 activity due to lack of necessary phosphorylation or activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 would decrease C1orf144 activity if C1orf144 is regulated by JNK signaling, either through direct phosphorylation or by regulating transcription factors that control C1orf144 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Targeting mTOR, Rapamycin would decrease C1orf144 activity if C1orf144 functions downstream of mTOR or is involved in processes such as protein synthesis, cell growth, or autophagy that are regulated by mTOR. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
As a GLUT1 inhibitor, WZB117 diminishes glucose uptake. If C1orf144 requires high glycolytic activity or is involved in pathways dependent on cellular glucose levels, WZB117 would lead to decreased C1orf144 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor, Bortezomib could lead to diminished C1orf144 activity indirectly by influencing the degradation of signaling molecules that activate C1orf144 or by stabilizing inhibitors of C1orf144. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
An Aurora kinase inhibitor, it would diminish C1orf144 activity if C1orf144 is involved in cell cycle regulation or other processes modulated by Aurora kinases. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
As a Bruton's tyrosine kinase inhibitor, Ibrutinib would decrease C1orf144 activity if C1orf144 is part of B-cell receptor signaling or other pathways involving Bruton's kinase. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR inhibitor, Gefitinib would lead to decreased C1orf144 activity if C1orf144 is involved in the EGFR signaling pathway or if its activity is modulated by downstream EGFR signaling events. | ||||||